For paracetamol (PCM, acetaminophen) poisoning, N-acetylcysteine (NAC) should be started promptly when indicated. Do not delay it if ingestion was >8 hours ago, the amount is unclear, or liver injury is suspected.
IV NAC: standard 3-bag regimen
Total: 300 mg/kg over 21 hours
| Phase | NAC dose | Infusion time |
|---|
| 1 | 150 mg/kg IV | over 1 hour |
| 2 | 50 mg/kg IV | over 4 hours |
| 3 | 100 mg/kg IV | over 16 hours |
For a 60 kg adult: 9 g, then 3 g, then 6 g.
Alternative IV 2-bag regimen
Used in some toxicology protocols to reduce infusion reactions:
- 200 mg/kg IV over 4 hours
- then 100 mg/kg IV over 16 hours
Total remains 300 mg/kg over 20 hours. Follow the protocol used by your hospital/poison center.
Oral NAC regimen
If IV NAC is unavailable or unsuitable:
- Loading: 140 mg/kg orally
- then 70 mg/kg orally every 4 hours for 17 doses
Total duration: 72 hours.
When to continue beyond the standard IV course
At the end of the 20-21 hour protocol, continue NAC if any of the following are present:
- Paracetamol level still detectable
- ALT/AST rising or abnormal
- INR elevated
- Acidosis, renal impairment, encephalopathy, or other evidence of liver failure
A common continuation regimen is 100 mg/kg IV over 16 hours, repeated with serial labs until paracetamol is undetectable and liver tests are clearly improving. This must be supervised by a toxicologist/hepatologist.
Practical cautions
- Adjust infusion volume, not the mg/kg dose, in small children, fluid-restricted patients, or heart/renal failure.
- Watch for IV NAC anaphylactoid reactions: flushing, urticaria, wheeze, hypotension. Pause or slow the infusion and treat clinically, then usually restart when stable.
- Give antiemetics if vomiting affects oral treatment.
- Use the paracetamol nomogram only for a single acute ingestion with a known time. It is not valid for repeated supratherapeutic ingestion or unknown time of ingestion.
The FDA labeled IV regimen is 150 mg/kg, then 50 mg/kg, then 100 mg/kg, total 300 mg/kg (
FDA prescribing information). Recent evidence suggests 2-bag and 3-bag IV regimens have comparable effectiveness, with fewer infusion-related adverse events reported in some two-bag protocols (
2025 systematic review).